Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates

Financial Performance - Inovio Pharmaceuticals reported a quarterly loss of $0.51 per share, better than the Zacks Consensus Estimate of a loss of$0.74, and an improvement from a loss of $1.31 per share a year ago, representing an earnings surprise of 31.08$0.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 30%, compared to zero revenues a year ago [2] Stock Performance - Inovio shares have increased by approximately 6% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current Zacks Rank for Inovio is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of$0.05 million, and for the current fiscal year, it is -$2.27 on revenues of$7.7 million [7] - The Medical - Biomedical and Genetics industry, to which Inovio belongs, is currently in the top 35% of Zacks industries, suggesting a favorable outlook for stocks within this sector [8]